StockData

Ultragenyx Pharmaceutical vs United Therapeutics

RARE and UTHR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How RARE and UTHR compare

United Therapeutics is the larger company, worth 16 times as much as Ultragenyx Pharmaceutical ($25.2B against $1.6B).

Ultragenyx Pharmaceutical grew revenue faster over the last twelve months (17.5% versus 2.5% for United Therapeutics).

United Therapeutics keeps more of each dollar of sales as profit, with a net margin of 41.6% compared with −81.7% at Ultragenyx Pharmaceutical.

United Therapeutics scores higher on the StockData Score (11 against 9 for Ultragenyx Pharmaceutical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricRAREUTHR
Size and price
Market cap$1.6B$25.2B
Share price$15.90$587.88
Change, 1 year−51.7%27.2%
Change, 5 years−79.2%204%
Beta (5Y)2.200.44
Employees1,3711,400
StockData Score
Total score911 (better)
Valuation score11
Growth score22
Performance score15 (better)
Health score5 (better)3
Dividend score00
Valuation
P/E–21.0×
P/S2.2× (better)8.0×
P/B–3.9×
EV/EBITDA–15.1×
P/FCF–23.1×
PEG–0.92
FCF yield−31.2%4.3% (better)
Fair value–$480.40
Margin of safety–−22.4%
Growth
Revenue growth (TTM)17.5% (better)2.5%
Revenue growth, 5Y average19.9% (better)16.5%
Net income growth (TTM)–5.5%
EPS growth (TTM)–9.0%
EPS growth, 5Y average–19.3%
Profitability
Gross margin–86.1%
Operating margin−73.6%44.4% (better)
Net margin−81.7%41.6% (better)
FCF margin−68.2%34.6% (better)
Return on equity–19.3%
Return on invested capital–29.7%
Financial health
Interest coverage–117×
Current ratio1.735.73 (better)
Altman Z-score−5.2921.79 (better)
Piotroski F-score58 (better)
Dividends and buybacks
Buyback yield–9.9%
Shareholder yield0.00%9.9% (better)
Ownership
Held by institutions108%97.4%
Held by insiders4.0%9.1%
Insider net buying, 12 months−$3.8M (better)−$1.4B
Short interest, % of float25.0%4.7%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.